

## UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549

August 3, 2017

Chad Kolean Vice President and Chief Financial Officer Cellectar Biosciences, Inc. 3301 Agriculture Drive Madison, WI 53716

Re: Cellectar Biosciences, Inc.

Preliminary Proxy Statement on Schedule 14A

Filed July 26, 2017 File No. 001-36598

Dear Mr. Kolean:

We have completed our review of your filing. We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence by the staff.

Division of Corporation Finance Office of Healthcare & Insurance

cc: Sarah Fortt, Vinson & Elkins LLP